Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Office of Women’s Health

Executive Summary

House Appropriations also recommends FDA's Office of Women's Health dedicate $500,000 "to supporting and implementing important women's health outreach activities, including the hormone replacement education initiative that was started in" FY 2003, the report states. Overall, the committee recommends a $600,000 increase for the office. Commissioner McClellan has said the education effort will stress short-term, low-dose use of hormone replacement therapy (1"The Pink Sheet" March 10, 2003, p. 28)...
Advertisement

Related Content

FDA women’s health appropriations
FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use
FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use
Advertisement
UsernamePublicRestriction

Register

PS042100

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel